目的通过对相关文献检索、汇总、整理及可视化分析,探讨药食同源类中药(MEHs)治疗骨髓抑制的组方配伍规律及潜在作用机制。方法检索Web of science、中国知网、万方数据知识服务平台、维普中文期刊、中国生物医学文献等数据库中有关中...目的通过对相关文献检索、汇总、整理及可视化分析,探讨药食同源类中药(MEHs)治疗骨髓抑制的组方配伍规律及潜在作用机制。方法检索Web of science、中国知网、万方数据知识服务平台、维普中文期刊、中国生物医学文献等数据库中有关中医药治疗骨髓抑制的文献,采用SPSS、CiteSpace等软件对所选文献中涉及的MEHs进行频数、功效、相关性等多元统计分析,总结MEHs治疗骨髓抑制的潜在机制。结果共纳入组方123组,涉及中药170味,其中MEHs 38味。聚类分析得到5对MEHs核心药物组合,主要功效包括补气养血、健脾祛湿、益气固肾等,其潜在作用机制涉及酪氨酸蛋白激酶2-转录激活蛋白5、β-连环蛋白等多条相关信号通路。结论临床MEHs缓解化学治疗所致骨髓抑制的相关报道主要集中在黄芪与当归、茯苓、党参等药味的配伍组合,并通过促进造血干细胞增殖、延缓造血干细胞衰老等机制发挥药效。展开更多
Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administr...Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.展开更多
文摘目的通过对相关文献检索、汇总、整理及可视化分析,探讨药食同源类中药(MEHs)治疗骨髓抑制的组方配伍规律及潜在作用机制。方法检索Web of science、中国知网、万方数据知识服务平台、维普中文期刊、中国生物医学文献等数据库中有关中医药治疗骨髓抑制的文献,采用SPSS、CiteSpace等软件对所选文献中涉及的MEHs进行频数、功效、相关性等多元统计分析,总结MEHs治疗骨髓抑制的潜在机制。结果共纳入组方123组,涉及中药170味,其中MEHs 38味。聚类分析得到5对MEHs核心药物组合,主要功效包括补气养血、健脾祛湿、益气固肾等,其潜在作用机制涉及酪氨酸蛋白激酶2-转录激活蛋白5、β-连环蛋白等多条相关信号通路。结论临床MEHs缓解化学治疗所致骨髓抑制的相关报道主要集中在黄芪与当归、茯苓、党参等药味的配伍组合,并通过促进造血干细胞增殖、延缓造血干细胞衰老等机制发挥药效。
文摘目的挖掘药食同源类中药治疗糖尿病足(diabetic foot,DF)的用药规律并探究其潜在分子机制,为开发针对DF的药膳疗法提供指导。方法通过检索中国知网、万方数据库和中国生物医学文献数据库中中药方剂治疗DF的临床文献,将其中药名称规范化后与药食同源类中药名单比较,得到药食同源来源方药集;采用中医传承辅助系统分析其用药规律,根据关联规则和聚类分析确定对DF具有治疗作用的药食同源类核心中药;获取核心中药的活性成分及其治疗DF的作用靶点,进行蛋白质相互作用(protein-protein interaction,PPI)分析以及基因本体(gene ontology,GO)和京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)富集分析;利用分子对接及动力学模拟,评估主要活性成分与其对应靶点的结合能力及结合稳定性。结果共筛选出药食同源类中药方剂521条,其性温平,味甘苦,入心、脾经,以补虚和清热药为主;进一步分析得到具有强关联性组合药对4个,获得4个治疗DF的药食同源潜在新组方药;筛选出当归、黄芪、金银花、甘草和桃仁为治疗DF的药食同源类核心中药,其作用机制主要涉及高级糖基化终末产物-受体(advanced glycation end products,AGE-RAGE)、缺氧反应因子-1(hypoxia-inducible factor-1,HIF-1)、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)等信号通路;核心中药包含的主要活性成分槲皮素和β-谷甾醇分别与治疗DF的关键靶点蛋白基质金属蛋白酶9(matrix metalloproteinase 9,MMP9)及氧化物酶体增殖物激活受体γ(peroxisome proliferator activated receptorγ,PPARγ)具有较好的结合能力及稳定性。结论药食同源类中药主要通过调节气血凝滞、筋脉阻塞等病机发挥治疗DF的作用,其关键活性成分可通过作用于DF主要治疗靶点MMP9、PPARγ等,进而调节AGE-RAGE、HIF-1和胰岛素抵抗等信号通路协同治疗DF,“黄芪-金银花-甘草”是极具潜力的DF药膳疗法新组方。
文摘Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.